Lineage Cell Therapeutics Inc (LCTX) — Free Cash Flow Generation Index

Latest as of March 2022: 1.00x

Lineage Cell Therapeutics Inc (LCTX) has a Free Cash Flow Generation Index of 1.00x as of March 2022. Free cash flow of $21.86 Million represents 1% of operating cash flow ($21.90 Million). See LCTX working capital efficiency to evaluate short-term liquidity relative to the company's equity base.

FCF Generation Index

1.00x

Free Cash Flow / Operating CF

Free Cash Flow

$21.86 Million

USD

Operating Cash Flow

$21.90 Million

USD

Capital Expenditures

$46.00K

USD

Lineage Cell Therapeutics Inc Free Cash Flow Generation Index (2022–2022)

Historical FCF Generation Index trend for Lineage Cell Therapeutics Inc across 1 annual periods. Explore Lineage Cell Therapeutics Inc (LCTX) cash flow to debt to assess how comfortably operating cash covers total debt obligations.

Annual Free Cash Flow Generation for Lineage Cell Therapeutics Inc (2022–2022)

Year-by-year Free Cash Flow Generation Index for Lineage Cell Therapeutics Inc. For the full company profile including market capitalisation, see LCTX market cap overview.

Year	FCG Index	Free Cash Flow (USD)	Operating CF	Capital Expenditures	YoY Change
2022	0.61x	$646.00K	$1.06 Million	$413.00K	—

FCG Index = Free Cash Flow / Operating Cash Flow. FCF = Operating CF + Capital Expenditures (capex stored negative).